

Suzanne George

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3010337/publications.pdf>

Version: 2024-02-01

85
papers

9,110
citations

94269

37
h-index

60497

81
g-index

87
all docs

87
docs citations

87
times ranked

9553
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. <i>Clinical Cancer Research</i> , 2022, 28, 1268-1276.	3.2	7
2	PET imaging of Gastrointestinal Stromal Tumors (GIST). , 2022, , .		0
3	A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases. <i>Modern Pathology</i> , 2022, 35, 794-807.	2.9	6
4	Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. <i>Clinical Cancer Research</i> , 2022, 28, 2397-2408.	3.2	6
5	Linking Genotype to Phenotype: Bench to Bedside. <i>Clinical Cancer Research</i> , 2022, , OF1-OF3.	3.2	1
6	Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 2579-2586.	3.2	4
7	Abstract LB565: Efficacy of a highly potent and selective KIT V654A inhibitor for treatment of imatinib resistant GIST. <i>Cancer Research</i> , 2022, 82, LB565-LB565.	0.4	0
8	Abstract CT168: Randomized phase 2 trial of sunitinib or cediranib in alveolar soft part sarcoma. <i>Cancer Research</i> , 2022, 82, CT168-CT168.	0.4	0
9	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021, 26, e639-e649.	1.9	29
10	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. <i>Cancer Discovery</i> , 2021, 11, 1508-1523.	7.7	20
11	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. <i>European Journal of Cancer</i> , 2021, 145, 132-142.	1.3	75
12	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
13	Differentiating leiomyosarcoma from leiomyoma: in support of an MR imaging predictive scoring system. <i>Abdominal Radiology</i> , 2021, 46, 4927-4935.	1.0	11
14	Early and Next-Generation KIT/PDGFR Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 672500.	1.3	35
15	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. <i>Oncologist</i> , 2021, 26, e2053-e2060.	1.9	19
16	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021, 155, 236-244.	1.3	19
17	Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options?. <i>Current Treatment Options in Oncology</i> , 2021, 22, 99.	1.3	3
18	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	0.8	56

#	ARTICLE	IF	CITATIONS
19	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. <i>Future Oncology</i> , 2020, 16, 4251-4264.	1.1	43
20	A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. <i>European Journal of Cancer</i> , 2020, 126, 21-32.	1.3	16
21	Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. <i>Molecular Cancer Research</i> , 2020, 18, 1302-1314.	1.5	24
22	Superior Vena Cava Syndrome associated with recurrent uterine adenocarcinoma. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100613.	0.3	3
23	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	0.8	61
24	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	5.1	224
25	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. <i>British Journal of Cancer</i> , 2020, 122, 1158-1165.	2.9	17
26	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2020, 21, 935-946.	5.1	186
27	Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade. <i>Clinical Cancer Research</i> , 2020, 26, 5078-5085.	3.2	59
28	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. <i>BMC Cancer</i> , 2020, 20, 99.	1.1	31
29	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7287-7293.	3.2	37
30	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 5135-5142.	3.2	14
31	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2019, 120, 612-620.	2.9	109
32	Characteristics of mismatch repair deficiency in sarcomas. <i>Modern Pathology</i> , 2019, 32, 977-987.	2.9	49
33	Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. <i>JCO Precision Oncology</i> , 2019, 2019, 1-11.	1.5	31
34	BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 335-341.	2.1	118
35	Soft Tissue and Uterine Leiomyosarcoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 144-150.	0.8	157
36	SARCO18_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. <i>Sarcoma</i> , 2018, 2018, 1-9.	0.7	13

#	ARTICLE	IF	CITATIONS
37	Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 536-563.	2.3	457
38	Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma. JAMA Oncology, 2018, 4, 1169.	3.4	6
39	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity, 2017, 46, 197-204.	6.6	400
40	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. Journal of Clinical Oncology, 2017, 35, 523-528.	0.8	58
41	YWHAE -rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecologic Oncology, 2017, 145, 531-535.	0.6	32
42	Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Targeted Oncology, 2017, 12, 277-288.	1.7	39
43	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer, 2017, 123, 3285-3290.	2.0	170
44	Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy. Oncologist, 2017, 22, 1265-1270.	1.9	24
45	A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARCO24 trial results.. Journal of Clinical Oncology, 2017, 35, 11005-11005.	0.8	30
46	Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2017, 35, 11011-11011.	0.8	16
47	Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors.. Journal of Clinical Oncology, 2017, 35, 2515-2515.	0.8	16
48	Whole exome analysis of patients (pts) with metastatic GIST (mGIST) demonstrating exceptional survival with imatinib (IM) therapy compared to those with short term benefit.. Journal of Clinical Oncology, 2017, 35, 11513-11513.	0.8	0
49	Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 758-786.	2.3	239
50	Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors. Clinical Imaging, 2016, 40, 880-884.	0.8	9
51	Role of Imaging in Management of Desmoid-type Fibromatosis: A Primer for Radiologists. Radiographics, 2016, 36, 767-782.	1.4	105
52	Molecular Subtypes of KIT/PDGFR Wild-Type Gastrointestinal Stromal Tumors. JAMA Oncology, 2016, 2, 922.	3.4	291
53	Risk Factors for Occult Uterine Sarcoma Among Women Undergoing Minimally Invasive Gynecologic Surgery. Journal of Minimally Invasive Gynecology, 2016, 23, 34-39.	0.3	19
54	Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.. Journal of Clinical Oncology, 2016, 34, 11007-11007.	0.8	11

#	ARTICLE	IF	CITATIONS
55	Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation.. Journal of Clinical Oncology, 2016, 34, 11043-11043.	0.8	4
56	Phase 1/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors.. Journal of Clinical Oncology, 2016, 34, TPS11070-TPS11070.	0.8	4
57	Uterine Sarcoma, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1321-1331.	2.3	58
58	Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment. Sarcoma, 2015, 2015, 1-5.	0.7	6
59	Biologic Activity of Autologous, Granulocyte Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	3.2	34
60	Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients. Journal of Gynecologic Oncology, 2014, 25, 306.	1.0	58
61	Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care. Oncologist, 2014, 19, 669-680.	1.9	61
62	Reply to inâ€bag morcellation for presumed myoma retrieval at laparoscopy. Cancer, 2014, 120, 4005-4005.	2.0	0
63	Recent advances in the treatment of gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology, 2014, 6, 115-127.	1.4	60
64	Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer, 2014, 120, 3154-3158.	2.0	166
65	Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer, 2014, 120, 738-743.	2.0	84
66	Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. European Journal of Cancer, 2014, 50, 981-986.	1.3	29
67	The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecologic Oncology, 2014, 132, 360-365.	0.6	133
68	Gastrointestinal Stromal Tumors, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 853-862.	2.3	96
69	Leiomyosarcoma. Hematology/Oncology Clinics of North America, 2013, 27, 957-974.	0.9	108
70	First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies. Clinical Cancer Research, 2013, 19, 909-919.	3.2	26
71	Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2012, 30, 2401-2407.	0.8	232
72	Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology, 2011, 67, 15-24.	1.1	59

#	ARTICLE	IF	CITATIONS
73	The role of imatinib plasma level testing in gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 45-50.	1.1	16
74	Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 871-879.	3.2	150
75	Reply to W.F. Pirl et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e51-e51.	0.8	2
76	Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 3154-3160.	0.8	295
77	Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure. <i>Clinical Cancer Research</i> , 2009, 15, 5902-5909.	3.2	133
78	Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. <i>European Journal of Cancer</i> , 2009, 45, 2818-2824.	1.3	44
79	Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. <i>Lancet, The</i> , 2007, 370, 2011-2019.	6.3	973
80	Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. <i>Current Oncology Reports</i> , 2007, 9, 323-327.	1.8	21
81	A Novel Role for CpG Oligonucleotides in Tumor Immunotherapy: CpG-ODN Induce Targeted Chemokine-Induced Lymphocyte Migration to the Peripheral Tissues in Humans.. <i>Blood</i> , 2007, 110, 1791-1791.	0.6	0
82	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet, The</i> , 2006, 368, 1329-1338.	6.3	2,349
83	Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. <i>European Journal of Cancer</i> , 2006, 42, 864-870.	1.3	24
84	Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors. <i>Annals of Internal Medicine</i> , 2006, 145, 660.	2.0	356
85	Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. <i>Current Treatment Options in Oncology</i> , 2002, 3, 489-496.	1.3	21